Inflammation is an Independent Risk Factor for Colonic Neoplasia in Patients with Ulcerative Colitis: a Case–Control Study
David T. Rubin,Dezheng Huo,Jami Kinnucan,Mina S. Sedrak,Nicole E. McCullom,Alana P. Bunnag,Elin P. Raun-Royer,Russell D. Cohen,Stephen B. Hanauer,John Hart,Jerrold R. Turner +10 more
Reads0
Chats0
TLDR
In a case-control study, increased inflammation is associated with CRN in patients with UC and use of immune modulators reduced the risk for CRN, indicating that these drugs have chemoprotective effects.About:
This article is published in Clinical Gastroenterology and Hepatology.The article was published on 2013-12-01 and is currently open access. It has received 233 citations till now. The article focuses on the topics: Primary sclerosing cholangitis & Inflammatory bowel disease.read more
Citations
More filters
Journal ArticleDOI
Microbiota and its relationship with Inflammatory Bowel Diseases: An overview
TL;DR: In this article , the authors discuss the effect of microbiota on patients with inflammatory bowel disease (IBD) to understand the role that their microbiota may play in efforts to treat both types of the disease, including ulcerative colitis and Crohn's disease.
Journal ArticleDOI
Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis.
Adam E. Mikolajczyk,Nathaniel A. Cohen,Sydeaka Watson,Max Ackerman,Sarah R. Goeppinger,John Hart,Jerrold R. Turner,David T. Rubin +7 more
TL;DR: It is suggested that even a single biopsy would adequately reflect the inflammation of the entire colorectum, suggesting that the use of histology as a clinical target and trial end point in UC is justified.
References
More filters
Journal ArticleDOI
The measurement of observer agreement for categorical data
J. R. Landis,Gary G. Koch +1 more
TL;DR: A general statistical methodology for the analysis of multivariate categorical data arising from observer reliability studies is presented and tests for interobserver bias are presented in terms of first-order marginal homogeneity and measures of interob server agreement are developed as generalized kappa-type statistics.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
TL;DR: Using new meta-analysis techniques, the risk of CRC in UC by decade of disease and defined the risk in pancolitics and children was determined and how risk varies with geography was estimated.
Journal ArticleDOI
Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
Steven H. Itzkowitz,Xianyang Yio +1 more
TL;DR: Observations of mice genetically prone to inflammatory bowel disease also develop colorectal cancer especially in the presence of bacterial colonization offer compelling support for the role of inflammation in colon carcinogenesis.
Journal ArticleDOI
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Matthew D. Rutter,Brian Saunders,Kay H. Wilkinson,Steve Rumbles,Gillian Schofield,Michael A. Kamm,Christopher S. Williams,Ashley B. Price,Ian C. Talbot,Alastair Forbes +9 more
TL;DR: In long-standing extensive ulcerative colitis, the severity of colonic inflammation is an important determinant of the risk of colorectal neoplasia and endoscopic and histological grading of inflammation could allow better risk stratification for surveillance programs.